New breast cancer drug identified as potential treatment for glioblastoma

The Ivy Brain Tumor Center at the Barrow Neurological Institute has published the results of its recent Phase 0 clinical trial of ribociclib (Kisqali, an anticancer drug)^®) for the treatment of recurrent glioblastoma. The agent, recently approved by the FDA for advanced bad cancer, is part of a newly discovered clbad of targeted therapies that compromises the division of cancer cells and could form the spine of a new badtail of drugs for patients with malignant brain tumors such as glioblastoma.

Glioblastoma presents unique and complex challenges compared to other types of cancer. You are not dealing with one entity, but rather a set of genetic variants that differ from patient to patient. This phase 0 clinical trial used a precision medicine approach to determine the glioblastoma subtypes that may react to ribociclib and how our patients' tumors developed resistance to this new treatment. "

Dr. Nader Sanai, Director of the Ivy Brain Tumor Center

The results of the trial show that ribociclib is particularly able to cross the blood-brain barrier, a key barrier that has inhibited drug development in patients with brain tumors for years and is effectively reaching its molecular target in the brain. cancer cells. The design of the Phase 0 experimental clinical trial also identifies a potential drug resistance mechanism, which the Ivy Brain Tumor Center's clinical trial team currently operates as part of a clinical trial. ongoing drug badtail testing in recurrent glioblastoma patients.

"This comprehensive study helped us identify a drug regimen that combines potent drugs to undermine a mechanism of glioblastoma resistance against ribociclib.In less than a year, we have made tremendous progress in the development of the drug. a new badtail of drugs, which is important considering the precious It is time that patients and doctors fight this disease, "said Dr. Sanai.